Acute Kidney Injury Requiring Renal Replacement Therapy and Critical Illness Myopathy: A Prospective Observational Trial

Sponsor
University of Iowa (Other)
Overall Status
Recruiting
CT.gov ID
NCT05287204
Collaborator
(none)
120
3
11
40
3.6

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether patients with acute kidney injury requiring renal replacement therapy have a higher incidence of muscle wasting than controls, and whether the course of recovery is longer compared to controls.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Observational study of patients initiated on RRT

Detailed Description

Acute kidney injury (AKI), the abrupt loss of kidney function, is a common complication that affects more than half of all ICU admissions, and it is associated with substantially higher rates of morbidity and mortality in both the short- and the long-term. This is especially true in patients who require renal replacement therapy (RRT), also known as dialysis. An understudied mechanism by which AKI-RRT may contribute to poor clinical outcomes, both in the hospital and after discharge, is through its impact on muscle mass and muscle function. AKI of any severity is known to alter tissue utilization of amino acids, and our preliminary data suggests that RRT in the ICU may exacerbate muscle dysfunction through the removal of large quantities of amino acids from the patient's plasma. In this proposal we plan to determine whether patients with AKI-RRT have greater lean muscle loss over 1 week than historic critically ill controls, whether patients with AKI-RRT have diminished recovery of muscle mass and function at one and three months following discharge compared to matched controls, and whether changes in plasma levels of amino acids during hospitalization correlate with loss of muscle function or lack of recovery.

Study Design

Study Type:
Observational
Anticipated Enrollment :
120 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Impact of Acute Kidney Injury Requiring Renal Replacement Therapy on the Incidence and Recovery From Critical Illness Muscle Wasting
Actual Study Start Date :
Nov 29, 2021
Anticipated Primary Completion Date :
Jun 30, 2022
Anticipated Study Completion Date :
Oct 31, 2022

Arms and Interventions

Arm Intervention/Treatment
AKI-RRT

These patients are those with acute kidney injury requiring renal replacement therapy.

Procedure: Observational study of patients initiated on RRT
Patients who are determined by the non-research hospital providers to need RRT.

Controls

Controls matched to AKI-RRT patients based on age within 10 years, sex, and ICU length of stay (within 2 days)

Outcome Measures

Primary Outcome Measures

  1. ICU Stage: Change in Rectus Femoris Cross-sectional Area [7 days]

    Muskuloskeletal ultrasound will measure RF CSA at the time of RRT initiation, and at 7 days thereafter

  2. Muscle cross sectional area- 1 month [1 month]

    RF CSA

  3. Muscle cross sectional area- 3 months [3 months]

    RF CSA

  4. Muscle Strength - knee extensor and dorsiflexion - 1 month [1 month]

    2) Maximal isometric knee extensor and dorsiflexion muscle strength measured as peak force production and rate of force development

  5. Muscle Strength - knee extensor and dorsiflexion - 3 month [3 months]

    2) Maximal isometric knee extensor and dorsiflexion muscle strength measured as peak force production and rate of force development

  6. Grip strength - 1 month [1 months]

    3) Maximal isometric grip strength

  7. Grip Strength - 3 months [3 months]

    3) Maximal isometric grip strength

  8. Muscle Strength - MRC-ss - 1 month [1 month]

    Medical Research Council sum score (MRC-ss),

  9. Muscle Strength - MRC-ss - 3 months [3 months]

    Medical Research Council sum score (MRC-ss),

  10. Physical Function - SPPB - 1 month [1 month]

    Short Performance Physical Battery

  11. Physical Function - SPPB - 3 months [3 months]

    Short Performance Physical Battery

  12. Physical Function - 6MWT - 1 month [1 month]

    Six-minute walk test

  13. Physical Function - 6MWT - 3 months [3 months]

    Six-minute walk test

  14. Physical Function - CFS - 1 month [1 month]

    Clinical Frailty Scale

  15. Physical Function - CFS - 3 months [3 months]

    Clinical Frailty Scale

  16. Quality of Life determined by EQ-5D-5L questionnaire - 1 month [1 month]

    EQ-5D-5L questionnaire

  17. Quality of Life determined by EQ-5D-5L questionnaire - 3 months [3 months]

    EQ-5D-5L questionnaire

  18. Quality of Life determined by FACIT-fatigue questionnaire - 1 month [1 month]

    FACIT-fatigue questionnaire

  19. Quality of Life determined by FACIT-fatigue questionnaire - 3 months [3 months]

    FACIT-fatigue questionnaire

Secondary Outcome Measures

  1. ICU Stage: Changes in Metabolome [7 days]

    We will use metabolomics to determine changes in the metabolome before and after RRT initiation.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 89 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  • 18 years old

  • On mechanical ventilation

  • AKI requiring RRT initiated within 72 hours of ICU admission.

Exclusion Criteria:
  • RRT of any kind at any time prior to ICU admission

  • underlying muscle disorders or muscle atrophy including quadriplegia or hemiplegia, history of stroke with residual muscle deficits, liver cirrhosis, alcohol dependence, active malignancy within 1 year, burns, or other baseline neuromuscular disease

  • pregnant patients

  • anticipated inability to engage in weight-bearing testing after discharge (e.g., traumatic/orthopedic surgery).

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Iowa Iowa City Iowa United States 52242
2 University of Kentucky Lexington Kentucky United States 40506
3 University of New Mexico Albuquerque New Mexico United States 87106

Sponsors and Collaborators

  • University of Iowa

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Benjamin Griffin, Assistant Professor, University of Iowa
ClinicalTrials.gov Identifier:
NCT05287204
Other Study ID Numbers:
  • 202002328
First Posted:
Mar 18, 2022
Last Update Posted:
Mar 18, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 18, 2022